Salman Fidahussein, MD
Critical Care Medicine · Lagrange, GANPI 1225298029
Payments from drug & device makers
Across 1,079 payments — averaging $789.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$710K
- Boehringer Ingelheim$68K
- Sunovion Pharmaceuticals Inc.$23K
- Genentech USA, Inc.$17K
- Mallinckrodt Enterprises LLC$11K
- Mylan Specialty L.p.$9K
- plus $15K from 25 others
What the payments were for
- Consulting fees$28,9123%
- Speaking & faculty fees$730,29886%
- Travel & lodging$68,3438%
- Food & beverage$22,0123%
- Education$2,7440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 761 | $710,192 |
| Boehringer Ingelheim | 104 | $67,630 |
| Sunovion Pharmaceuticals Inc. | 61 | $23,167 |
| Genentech USA, Inc. | 23 | $16,956 |
| Mallinckrodt Enterprises LLC | 10 | $10,684 |
| Mylan Specialty L.p. | 16 | $8,961 |
| AbbVie | 27 | $7,177 |
| Intuitive Surgical | 8 | $3,690 |
| Mallinckrodt Hospital Products Inc. | 1 | $2,150 |
| GSK | 27 | $588 |
| Insmed, Inc. | 8 | $253 |
| Pulmonx Corporation | 2 | $105 |
| Medtronic | 1 | $88 |
| BD | 3 | $85 |
| Astellas Pharma US Inc | 1 | $75 |
| Regeneron Healthcare Solutions, Inc. | 3 | $70 |
| Sanofi | 2 | $57 |
| CSL Behring | 3 | $57 |
| Johnson & Johnson | 3 | $45 |
| Scpharmaceuticals Inc. | 1 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Amgen | 2 | $33 |
| Stryker | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| United Therapeutics Corporation | 2 | $17 |
| Resmed Corp | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Veran Medical Technologies, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$473,857
- AIRSUPRA$138,876
- FASENRA$71,640
- OFEV$26,103
- LONHALA MAGNAIR$21,962
- ACTHAR$12,747
- XOLAIR$11,902
- Yupelri$8,756
- BREZTRI AEROSPHERE$5,604
- TEFLARO$3,995
- Da Vinci Surgical System$3,494
- AVYCAZ$2,362
- STIOLTO RESPIMAT$1,075
- NUCALA$125
- DA VINCI SP$123
- TRELEGY ELLIPTA$104
How this compares
$852,309 in reported general payments places this provider in the 95th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $215,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $69,867 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 87 | $64,392 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,821 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,326 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $2,322 |
| Roflumilast | 39 | $1,828 |
| Fluticasone Propionate | 28 | $343 |
| Montelukast Sodium | 50 | $286 |
| Pantoprazole Sodium | 11 | $19 |
| Azithromycin | 12 | $5 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $67,630 | $221,29128 claims |
| GSKTrelegy Ellipta | $588 | $69,86798 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $710,192 | $68,718105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Lagrange
- Bruce FriedmanAugusta$653K
- Paul WeinbergLawrenceville$453K
- Lawrence KaplanLawrenceville$360K
- Gregory MauldinSnellville$221K
- Clark McDonoughDalton$97K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- Asif SaberiMarietta$47K
- April McDonaldGainesville$41K
- Matthew SchmittAtlanta$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.